Serum endostatin levels in patients with hepatocellular carcinoma [1]

Annals of Oncology

Volumn 11, Issue 6, 2000, Pages 761-762

  Yamagata, M ^a   Shiratori, Y ^a   Dan, Y ^a   Shiina, S ^a   Takayama, T ^b   Makuuchi, M ^b   Omata, M ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; ENDOSTATIN; VASCULOTROPIN;

ANGIOGENESIS; CANCER STAGING; COLLAGEN SYNTHESIS; CONTROLLED STUDY; DISEASE ASSOCIATION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOPATHOLOGY; LETTER; LIVER CELL CARCINOMA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL;

EID: 0033744651     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008318526938     Document Type: Letter

References (7)

1. Endostatin: An endogenous inhibitor of angiogenesis and tumor growth
2. Structure, function and tissue forms of the C-terminal globular domain of collagen XVIII containing the angiogenesis inhibitor endostatin
3. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance
4. Vascular endothelial growth factor is a secreted angiogenic mitogen
5. Classification of macroscopic stage
6. Serum concentrations of endostatin in patients with vulvar cancer
7. Constitutional production and thronbin-induced release of vascular endothelial growth factor by human megakaryocytes and platelets